Overview
- In late June, entrepreneurs and analysts in India reported that low‑cost generic GLP‑1s have not produced the expected sales surge, with makers cutting targets and observers blaming patient retention, self‑injection friction and conservative prescribing.
- Approved oral versions of GLP‑1s — including Wegovy in tablet form and Lilly’s Foundayo — plus Phase II success for new small‑molecule pills have increased consumer demand forecasts while drugmakers push into larger Phase III trials.
- Employers and insurers are responding to rising use and high per‑patient costs by tightening eligibility, reconsidering coverage and exploring alternative programs, even as early Medicare pilots promise lower copays for some beneficiaries.
- Real‑world signals such as high discontinuation and wearable/claims reports of reduced activity, together with common side effects, are prompting clinicians and public‑health leaders to urge caution about long‑term, chronic use.
- Retailers and pharmacy chains are expanding distribution and support programs for GLP‑1 patients while supermarkets and grocery chains adjust product ranges and portioning to changing shopper tastes driven by the drugs’ appetite effects.